Novel amorphous active pharmaceutical ingredients

Novel amorphous active pharmaceutical ingredients

The present invention is directed to a solid and substantially amorphous active pharmaceutical ingredient, to an oral pharmaceutical formulation comprising said substantially amorphous active pharmaceutical ingredient, as well as to a method for the manufacture of the same. The invention is also dir...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: IVARSSON, Caroline, FAGERBERG, Jonas, ÅSBERG, Peter
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator IVARSSON, Caroline
FAGERBERG, Jonas
ÅSBERG, Peter
description The present invention is directed to a solid and substantially amorphous active pharmaceutical ingredient, to an oral pharmaceutical formulation comprising said substantially amorphous active pharmaceutical ingredient, as well as to a method for the manufacture of the same. The invention is also directed to the use of a particulate anhydrous and substantially amorphous mesoporous magnesium carbonate (MMC) to stabilize an active pharmaceutical ingredient (API).
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU2021266595A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU2021266595A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU2021266595A13</originalsourceid><addsrcrecordid>eNrjZDD0yy9LzVFIzM0vKsjILy1WSEwuySxLVSjISCzKTUxOLS3JTE7MUcjMSy9KTclMzSsp5mFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFQE15qSXxjqFGBkaGRmZmppamjobGxKkCAIqaLTE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Novel amorphous active pharmaceutical ingredients</title><source>esp@cenet</source><creator>IVARSSON, Caroline ; FAGERBERG, Jonas ; ÅSBERG, Peter</creator><creatorcontrib>IVARSSON, Caroline ; FAGERBERG, Jonas ; ÅSBERG, Peter</creatorcontrib><description>The present invention is directed to a solid and substantially amorphous active pharmaceutical ingredient, to an oral pharmaceutical formulation comprising said substantially amorphous active pharmaceutical ingredient, as well as to a method for the manufacture of the same. The invention is also directed to the use of a particulate anhydrous and substantially amorphous mesoporous magnesium carbonate (MMC) to stabilize an active pharmaceutical ingredient (API).</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20221201&amp;DB=EPODOC&amp;CC=AU&amp;NR=2021266595A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20221201&amp;DB=EPODOC&amp;CC=AU&amp;NR=2021266595A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>IVARSSON, Caroline</creatorcontrib><creatorcontrib>FAGERBERG, Jonas</creatorcontrib><creatorcontrib>ÅSBERG, Peter</creatorcontrib><title>Novel amorphous active pharmaceutical ingredients</title><description>The present invention is directed to a solid and substantially amorphous active pharmaceutical ingredient, to an oral pharmaceutical formulation comprising said substantially amorphous active pharmaceutical ingredient, as well as to a method for the manufacture of the same. The invention is also directed to the use of a particulate anhydrous and substantially amorphous mesoporous magnesium carbonate (MMC) to stabilize an active pharmaceutical ingredient (API).</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDD0yy9LzVFIzM0vKsjILy1WSEwuySxLVSjISCzKTUxOLS3JTE7MUcjMSy9KTclMzSsp5mFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFQE15qSXxjqFGBkaGRmZmppamjobGxKkCAIqaLTE</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>IVARSSON, Caroline</creator><creator>FAGERBERG, Jonas</creator><creator>ÅSBERG, Peter</creator><scope>EVB</scope></search><sort><creationdate>20221201</creationdate><title>Novel amorphous active pharmaceutical ingredients</title><author>IVARSSON, Caroline ; FAGERBERG, Jonas ; ÅSBERG, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU2021266595A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2022</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>IVARSSON, Caroline</creatorcontrib><creatorcontrib>FAGERBERG, Jonas</creatorcontrib><creatorcontrib>ÅSBERG, Peter</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>IVARSSON, Caroline</au><au>FAGERBERG, Jonas</au><au>ÅSBERG, Peter</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Novel amorphous active pharmaceutical ingredients</title><date>2022-12-01</date><risdate>2022</risdate><abstract>The present invention is directed to a solid and substantially amorphous active pharmaceutical ingredient, to an oral pharmaceutical formulation comprising said substantially amorphous active pharmaceutical ingredient, as well as to a method for the manufacture of the same. The invention is also directed to the use of a particulate anhydrous and substantially amorphous mesoporous magnesium carbonate (MMC) to stabilize an active pharmaceutical ingredient (API).</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_AU2021266595A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title Novel amorphous active pharmaceutical ingredients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T21%3A44%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=IVARSSON,%20Caroline&rft.date=2022-12-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU2021266595A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true